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Abstract: Chronic viral hepatitis is the most important risk factor for
progression to hepatocellular carcinoma (HCC). To identify genetic
risk factors for progression to HCC in individuals with chronic hepa-
titis C virus (HCV), we analyzed 467,538 SNPs in 212 Japanese indi-
viduals with chronic HCV with HCC and 765 individuals with chronic
HCV without HCC. We identiﬁed one intronic SNP in the DEPDC5
locus on chromosome 22 associated with HCC risk and conﬁrmed
the association using an independent case–control population (710
cases and 1625 controls). The association was highly signiﬁcant
when we analyzed the stages separately as well as together
(rs1012068, P(combined) = 1.27  1013, odds ratio = 1.75). The sig-
niﬁcance level of the association further increased after adjustment
for gender, age, and platelet count (P = 1.35  1014, odds
ratio = 1.96). Our ﬁndings suggest that common variants within
the DEPDC5 locus affect susceptibility to HCC in Japanese individuals
with chronic HCV infection.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
The global incidence of hepatocellular carcinoma (HCC) is
increasing, and it remains among the top three cancer killers
worldwide. Chronic liver disease due to viral hepatitis B and C
infection underlies HCC in more than 70% of cases. In cirrhotic
patients with HCV infection, the annual HCC development ratesJournal of Hepatology 20
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alence of HCV infection is 2%, and despite recent successes from
ﬁrst generation direct acting antivirals, it is likely that the HCV-
related HCC medical and economic burden will continue to
increase during the current decade.
Surveillance programs for early detection of HCC have a posi-
tive impact on patient outcomes, and thus have been endorsed by
clinical practice guidelines. Different studies have identiﬁed the
key factors deﬁning at-risk populations, such as male gender, bil-
irubin and AFP levels, portal hypertension indicators (e.g. HVPG
measurements, platelet count, presence of varices), and viral
genotypes [1]. However, none is routinely used to stratify risk
within cirrhotic patients. Some cohort studies have underlined
differences in HCC incidence according to patient’s ethnicity,
which can be about 2-fold higher in Japan than in the Western
countries (5-year cumulative incidence of 30% and 17%, respec-
tively) [2]. This fact suggests that inherited polymorphic traits
could favor HCC development in certain populations. In this
sense, previous data suggest that ethnic background seems to
inﬂuence disease outcome and response to therapies in liver dis-
eases. For example, a genetic polymorphism in IL28B gene deﬁnes
a better response to conventional HCV therapy in European pop-
ulations as opposed to African-American populations [3]. Thus,
the consequences of an accurate stratiﬁcation of risk based on
clinical or genomic parameters might have direct clinical implica-
tions. First, it would facilitate the conduction of chemoprevention
trials by optimizing the selection of the target population. In prin-
ciple, selection of high-risk patients would signiﬁcantly reduce
sample size and duration of this type of trials [4]. Notably, not
a single drug has been approved yet by regulatory agencies to
prevent HCC development in cirrhotic patients of any etiology.
Second, once the risk factors are thoroughly validated, it might
reﬁne the surveillance policies in speciﬁc populations.
Genome-wide association studies (GWAS) were recently
developed as an unbiased high-throughput genotyping tool to
discover common genetic traits associated with human diseases.
Between 2005 and June 2011, a total of 951 of such studies were
deposited at the National Institutes of Health (www.genome.gov/
gwastudies). Their hypothesis-free nature (i.e. unsupervised anal-
ysis of hundreds of thousands of single-nucleotide polymor-
phisms (SNP) in large cohorts of individuals) favors both false
positive and negative results. The massive amount of statistical
tests performed requires stringent corrections for multiple12 vol. 57 j 213–214
Table 1. Published GWAS in hepatocellular carcinoma.
Author, [Ref.] Samples analyzed Etiology of liver 
disease
DNA regions Candidate 
genes
Effect size/odds ratio 
(95% CI)HCC 
(validation)
Controls 
(validation)
Total
Miki et al., [7] 212 (710) 765 (1625) 3312 Hepatitis C Chr 22q12.2 DEPDC5 1.75 (1.51-2.03)
Kumar et al., [9] 721 (673) 2890 (2596) 6880 Hepatitis C Chr 6p21.33 MICA 1.39 (1.27-1.63)
Zhang et al., [8] 348 (1962) 359 (1430) 4099 Hepatitis B Chr 1p36.22 UBE4B-
KIF1B-PDG
0.61 (0.55-0.67)
Clifford et al., [10] 180 (337) 206 (336) 1059 Hepatitis B/C Chr 13q12.11
Chr 2q14.1
TPTE2
Non-coding
0.27 (0.19-0.39)
3.38 (2.07-5.52)
identified
International Hepatologycomparisons and robust validation in independent cohorts. Other
potential sources of error are related to selection of study partic-
ipants and genotyping inaccuracies [5]. Despite their wide appli-
cation in different liver diseases, until 2010 few data was
available on molecular epidemiology in HCC [6].
The study by Miki et al. [7] is the last of a recent series of
GWAS focused on HCC (Table 1 [7–10]). Authors analyzed a large
set of HCV Japanese carriers (n = 3312) using a case–control
design, and a two-step approach. In the training set (272 cases
and 765 controls), they interrogated 467,538 germ-line SNPs
and identiﬁed one, rs1012068, signiﬁcantly associated with the
risk of developing HCC, with an odds ratio of 2.2. The SNP
retained signiﬁcant predictive power upon logistic regression
modeling including age, gender, and platelet count. This was fur-
ther conﬁrmed in a validation set including 710 cases and 1625
controls, using a different genotyping technique. The SNP is
located on chromosome 22, and by using ﬁne mapping studies,
the authors identiﬁed DEPDC5 as the target gene harboring the
different genotypes. Despite the fact that the function of this gene
is unknown, there is some evidence of aberrations affecting its
locus in human cancer (e.g. glioblastoma). The study has several
limitations, noteworthy the lack of information regarding the
stage of ﬁbrosis and/or cirrhosis of patients and controls, which
is critical to adjust for risk development. Only adjustment for
platelet count, a suboptimal surrogate of portal hypertension,
was provided. It is also concerning that such a well-powered
study was unable to identify previously reported SNPs in other
candidate genes (i.e. MICA) already documented as deﬁning
high-risk populations in Japanese patients [9]. Unfortunately, fail-
ure to reproduce the associations between SNPs and disorders is
not uncommon in GWAS [5], which emphasizes the importance
of study design in these initiatives. In the case of HCV–HCC stud-
ies, selection of controls was heterogeneous among studies, one
including HCV infected individuals [7], while the other also
included healthy controls [9], which could partially justify
results’ discrepancy.
At last, the concept of deﬁning high-risk populations based on
germ-line SNPs has entered the HCC ﬁeld, following what has
been reported in several solid tumors. The lack of reproducibility
among the SNPs found in HCC reports (Table 1) reﬂects both the
high molecular heterogeneity linked to the initiation and pro-214 Journal of Hepatology 201gression of this neoplasm, along with some methodological
issues in study design that need to be overcome in future inves-
tigations. Further studies in Asian and Western HCV-related HCC
patients should conﬁrm the relevance of the SNPs identiﬁed in
these seminal investigations. Ideally, these ﬁndings will ulti-
mately reﬁne surveillance interventions and clear the path for
trial enrichment testing chemoprevention strategies.Conﬂict of interest
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